ロード中...
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
A subgroup of patients with severe COVID-19 suffers from progression to acute respiratory distress syndrome and multiorgan failure. These patients present with progressive hyperinflammation governed by proinflammatory cytokines. An interdisciplinary COVID-19 work flow was established to detect patie...
保存先:
| 出版年: | Leukemia |
|---|---|
| 主要な著者: | , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Nature Publishing Group UK
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7282206/ https://ncbi.nlm.nih.gov/pubmed/32518419 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-020-0891-0 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|